Press coverage about Forward Pharma A/S (NASDAQ:FWP) has trended somewhat positive this week, AlphaOne reports. The research firm, a service of Accern, rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Forward Pharma A/S earned a daily sentiment score of 0.14 on AlphaOne’s scale. AlphaOne also assigned media stories about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.
Shares of Forward Pharma A/S (NASDAQ:FWP) traded up 8.18% during midday trading on Friday, hitting $21.96. 70,493 shares of the company’s stock traded hands. Forward Pharma A/S has a 1-year low of $14.89 and a 1-year high of $33.00. The firm’s market capitalization is $1.04 billion. The company has a 50 day moving average price of $19.74 and a 200 day moving average price of $22.41.
A number of equities analysts have weighed in on the stock. Jefferies Group LLC set a $22.00 price objective on shares of Forward Pharma A/S and gave the company a “hold” rating in a research report on Tuesday, April 18th. JMP Securities lowered shares of Forward Pharma A/S from an “outperform” rating to a “market perform” rating in a research note on Monday, April 3rd. Zacks Investment Research upgraded shares of Forward Pharma A/S from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research note on Wednesday, April 5th. Finally, Leerink Swann set a $28.00 price objective on shares of Forward Pharma A/S and gave the stock a “buy” rating in a research note on Monday, April 3rd.
TRADEMARK VIOLATION WARNING: “Forward Pharma A/S (FWP) Given Daily Coverage Optimism Score of 0.14” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://transcriptdaily.com/2017/06/17/forward-pharma-as-fwp-getting-somewhat-favorable-press-coverage-study-shows-updated.html.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.